| Identification | Back Directory | [Name]
ZG-10 | [CAS]
1408077-04-2 | [Synonyms]
ZG-10
Benzamide, 4-[[4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- | [Molecular Formula]
C28H27N7O2 | [MOL File]
1408077-04-2.mol | [Molecular Weight]
493.56 |
| Hazard Information | Back Directory | [Description]
ZG-10 is a JNK1 inhibitor, which targets JNK and p38 signaling. | [Uses]
ZG-10 (JNK-IN-2) is a JNK inhibitor, with IC50 values of 809 nM, 1140 nM and 709 nM for JNK1, JNK2, and JNK3, respectively. ZG-10 (JNK-IN-2) is a potential anti-SARS-CoV-2 agent[1][2]. | [Definition]
ChEBI: 4-[[4-(dimethylamino)-1-oxobut-2-enyl]amino]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide is a member of benzamides. | [IC 50]
JNK1: 809 nM (IC50); JNK2: 1140 nM (IC50); JNK3: 709 nM (IC50) | [References]
[1] Tinghu Zhang, et al. Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012 Jan 27;19(1):140-54. DOI:10.1016/j.chembiol.2011.11.010
[2] Rui Zhang, et al. Inflammatory activation and immune cell infiltration are main biological characteristics of SARS-CoV-2 infected myocardium. Bioengineered. 2022 Feb;13(2):2486-2497. DOI:10.1080/21655979.2021.2014621 |
|
|